The Berberine-TMAO Study: Gut Microbiota Remodeling reduced TMAO Production and Vascular Health

1. Overview

Reason Behind the Study

Atherosclerosis, the buildup of fatty plaques inside arteries, is the pathological foundation for most cardiovascular diseases, which remain the leading cause of death worldwide. For decades, research focused on cholesterol, blood pressure, and inflammation as the primary drivers of this disease. However, a series of landmark discoveries beginning in 2011 identified a surprising new culprit: trimethylamine-N-oxide (TMAO), a metabolite produced not by human cells but by gut bacteria. When people consume foods rich in choline, phosphatidylcholine, or carnitine, compounds abundant in red meat, eggs, and animal organs, certain gut microbes convert these nutrients into trimethylamine (TMA), which the host liver then oxidises into TMAO. Elevated circulating TMAO proved to be an independent risk factor for atherosclerosis and adverse cardiovascular events, distinct from traditional markers like LDL cholesterol . This opened an urgent question: could a drug that reduces TMAO production by gut bacteria treat or prevent atherosclerosis?

Berberine (BBR) is a natural isoquinoline alkaloid extracted from medicinal plants such as Coptis chinensis and Berberis vulgaris. It has been used in China for decades as an over-the-counter treatment for bacterial diarrhoea, and since 2004 clinical studies have demonstrated its efficacy against hyperlipidaemia and type 2 diabetes . Berberine was also known to reduce atherosclerotic plaque in animal models. Yet a profound puzzle sat at the centre of berberine research: its oral bioavailability is less than one percent, meaning that over 99 percent of ingested BBR is never absorbed into the bloodstream . How could a drug that barely enters the body produce such clear cardiovascular and metabolic benefits?

Goals

The study, led by Professor Jian-Dong Jiang and Professor Yan Wang at the Chinese Academy of Medical Sciences, in collaboration with Professor Qian Tong at Jilin University, set out to answer this question. Published in Signal Transduction and Targeted Therapy in July 2022, the research had four primary objectives. First, to determine whether berberine reduces TMA and TMAO production in the gut microbiota of living animals. Second, to identify the precise enzymatic targets through which berberine and its metabolites act on the choline-TMA-TMAO pathway. Third, to characterise the unique mechanism, described by the researchers as a vitamin-like effect, by which berberine cycles between its oxidised and reduced forms while inhibiting multiple steps in the TMAO production cascade. Fourth, to test whether these mechanistic findings translated into measurable reductions in atherosclerotic plaque in human patients .

Key Eye-Opening Findings

The study produced a discovery that fundamentally reframes understanding of how a poorly absorbed natural compound can exert systemic therapeutic effects. Oral berberine reduces TMAO biosynthesis in the intestine not by entering the bloodstream, but by acting directly inside the gut on the bacterial enzyme machinery that produces TMA. Specifically, berberine is partially reduced by nitroreductase (NR) enzymes from gut bacteria into its metabolite dihydroberberine (dhBBR). This dhBBR then acts as a potent inhibitor of two key bacterial targets: the choline-TMA lyase enzyme complex (CutC/CutD), which converts dietary choline into TMA, and the flavin-containing monooxygenase (FMO) enzyme system, which further converts TMA into TMAO within the gut itself . Critically, dhBBR is then oxidised back to BBR, while BBR is again reduced to dhBBR, creating a continuous, self-sustaining inhibitory cycle. The researchers termed this a vitamine-like effect, drawing a direct parallel to how vitamin C and dehydroascorbic acid cycle between reduced and oxidised forms to maintain their biological activity. In this mode, berberine does not act as a conventional drug that binds a single receptor at a fixed dose; rather, it behaves like a catalytic cofactor, continuously regenerating its active inhibitory form as long as it is present in the gut .

The clinical significance of this mechanism was demonstrated in a trial of 21 patients with hyperlipidaemia and atherosclerosis. After four months of oral BBR (0.5 grams twice daily), patients showed an average reduction in atherosclerotic plaque score of 3.2 percent, while a comparator group of 12 patients receiving standard therapy (rosuvastatin plus aspirin, clopidogrel sulfate, or ticagrelor) saw their plaque scores increase by 1.9 percent over the same period. Faecal TMA and TMAO decreased by 38 and 29 percent respectively, and plasma TMA and TMAO dropped by 37 and 35 percent. This was the first clinical evidence that targeting the gut microbial TMAO pathway with berberine could produce measurable regression of atherosclerotic plaque in humans .

2. Study in Detail

Design and Experimental Approach

The study employed a comprehensive, multi-tiered experimental design that progressed from in vitro enzymatic assays through animal models to a human clinical trial. This structure allowed the researchers to establish not only that berberine reduces TMAO, but precisely how it does so at the molecular level.

Animal Models

Two primary animal models were used. High-fat diet (HFD)-fed Golden Syrian hamsters served as the atherosclerosis model for the main mechanistic investigations, as hamsters develop diet-induced atherosclerotic lesions with features resembling human disease. HFD-fed Sprague-Dawley rats provided gut microbial samples for in vitro culture experiments. Additional confirmatory studies were conducted in C57BL/6J and ApoE knockout mice fed choline-supplemented diets .

Methodology

The researchers deployed an arsenal of complementary techniques:

· LC-MS/MS Quantification: A targeted liquid chromatography-tandem mass spectrometry method was developed and validated for precise quantification of TMA and TMAO in faecal samples, plasma, and bacterial culture media. This analytical foundation enabled measurement of the choline-TMA-TMAO pathway activity across all experimental systems .

· Intraperitoneal versus Oral Administration: To prove that TMAO reduction required gut microbial exposure, berberine was administered both orally and by intraperitoneal (ip) injection. Oral BBR dramatically reduced faecal and plasma TMA/TMAO, whereas ip injection, which delivered higher blood levels of BBR but bypassed the gut lumen, produced no change in TMA or TMAO levels. This elegantly demonstrated that the site of action was the gut microbiota, not host tissues .

· Faecal Transplantation: Gut bacteria from HFD-fed hamsters treated with BBR were transplanted into untreated HFD-fed hamsters. The recipients showed significantly reduced plasma and faecal TMA/TMAO compared to those receiving microbiota from untreated donors, confirming that BBR-modified gut microbiota alone was sufficient to recapitulate the TMAO-lowering effect .

· Heterologous Expression of CutC: The choline-TMA lyase enzyme (CutC) was expressed heterologously in E. coli to test whether dhBBR directly inhibits this specific enzyme. In this isolated system, dhBBR significantly inhibited choline-to-TMA conversion, proving CutC as a direct molecular target .

· In Vitro Bacterial Strain Screening: Fifteen individual intestinal bacterial strains were tested for TMA production capacity and sensitivity to BBR. Strains such as Proteus mirabilis, Shigella boydii, and Bacteroides fragilis showed significant TMA reduction after BBR treatment, while others, including Pseudomonas aeruginosa, did not, demonstrating that the effect is specific to TMA-producing bacteria .

· Clinical Trial: The human component involved 33 patients total, with 21 receiving oral BBR (0.5 g twice daily for four months) and 12 receiving standard cardiovascular medications. Plaque scores were assessed before and after treatment, alongside faecal and plasma TMA/TMAO measurements .

3. Key Findings

Oral BBR Requires Gut Microbial Contact, Not Systemic Absorption

The ip versus oral administration experiment was definitive. Oral BBR produced rapid and significant reductions in faecal TMA and TMAO (28 to 98 percent decreases at various time points over 24 hours) along with corresponding plasma reductions (37 to 64 percent). Intraperitoneal BBR, despite achieving higher blood concentrations, produced no change in TMA or TMAO levels whatsoever. This result proved that BBR's TMAO-lowering effect operates entirely through interaction with gut microbiota, resolving the long-standing mystery of how a poorly absorbed drug exerts systemic cardiovascular benefits .

Dihydroberberine Is the Active Inhibitor

The gut bacterial enzyme nitroreductase (NR) reduces BBR to dihydroberberine (dhBBR). In head-to-head comparisons using cultured gut microbiota, dhBBR proved more potent than BBR at inhibiting TMA and TMAO production. At 0.06 mM, dhBBR achieved a 50 percent reduction in TMA production, comparable to the effect of 0.3 mM of DMB (3,3-dimethyl-1-butanol), a previously characterised competitive inhibitor of CutC. DhBBR was approximately five times more potent than DMB on a molar basis, establishing dhBBR as a strong natural inhibitor of the choline-TMA lyase enzyme complex .

DhBBR Directly Inhibits Bacterial CutC

Using E. coli heterologously expressing the CutC enzyme with its activase CutD, the researchers demonstrated that dhBBR directly inhibits the conversion of choline to TMA. In this isolated enzymatic system, with all host factors removed, dhBBR produced significant suppression of TMA generation, providing direct molecular evidence that CutC is a specific target of dhBBR .

DhBBR Also Inhibits Gut Bacterial FMO

Beyond CutC inhibition, dhBBR was found to suppress the FMO enzyme system within gut bacteria that converts TMA to TMAO locally in the intestine. This means that berberine, through dhBBR, attacks the TMAO production pathway at two sequential enzymatic steps: the CutC/CutD-catalysed conversion of choline to TMA, and the FMO-catalysed conversion of TMA to TMAO. This dual inhibition may explain the potency of BBR in reducing TMAO levels .

The Vitamin-Like Redox Cycle

The most conceptually novel finding was the cycling mechanism. DhBBR, having inhibited CutC and FMO, is oxidised back to BBR. This BBR can then be re-reduced to dhBBR by bacterial nitroreductase, regenerating the active inhibitor. This continuous interconversion, analogous to the cycling between ascorbic acid and dehydroascorbic acid that maintains vitamin C activity, means that BBR functions catalytically rather than stoichiometrically. A relatively small amount of BBR can sustain ongoing inhibition of the TMAO pathway through repeated redox cycling. This mechanism explains how a poorly absorbed, modestly dosed compound can produce sustained biological effects .

Animal Model Atherosclerosis Protection

In HFD-fed hamsters, oral BBR reduced intestinal TMAO biosynthesis, lowered blood TMAO levels, and interrupted plaque formation in blood vessels. The anti-atherosclerotic effect was directly attributable to TMAO reduction, as the experimental design isolated this pathway .

Clinical Plaque Regression in Humans

The 21 patients receiving BBR for four months experienced a mean plaque score decrease of 3.2 percent, which was statistically significant. In contrast, the 12 patients on standard therapy (statins plus antiplatelet agents) saw their plaque scores increase by a mean of 1.9 percent. Faecal TMA and TMAO dropped by 38 and 29 percent, while plasma TMA and TMAO decreased by 37 and 35 percent. These results provided the first clinical validation that the CutC/FMO inhibitory mechanism identified in vitro and in animals translates to measurable, clinically relevant plaque reduction in human atherosclerosis .

4. Lessons Learnt

Poor oral bioavailability can be a feature, not a flaw.

The study fundamentally challenges the conventional pharmaceutical wisdom that drugs must be well absorbed to be effective. Berberine's near-zero oral bioavailability is precisely what positions it in the gut lumen to interact with the microbial enzyme machinery. Its therapeutic target is not a human receptor but a bacterial enzyme complex. This re-framing has broad implications for natural product pharmacology and for the design of drugs targeting the gut microbiome .

A drug can function like a vitamin.

The characterisation of the dhBBR/BBR redox cycle as vitamin-like introduces a novel mechanism of drug action. Rather than a drug molecule binding a receptor once and being cleared, berberine participates in a regenerative catalytic cycle in which the active inhibitory form is continuously replenished by the metabolic activity of the very microbiota it modulates. This mode of action may exist among other natural products with unexplained efficacy despite poor absorption .

The gut microbiome is a legitimate and accessible drug target.

The study provides a complete translational arc from enzymatic target identification through animal model validation to human clinical benefit for a gut-microbiome-targeted cardiovascular therapy. It demonstrates that reducing TMAO production at its microbial source is a viable therapeutic strategy for atherosclerosis, independent of and potentially complementary to cholesterol lowering and antiplatelet therapy .

Diet-drug interactions occur through microbial intermediaries.

The clinical finding that BBR reduced plaque while standard therapy did not, in patients who were likely continuing their habitual diets, suggests that pharmacologically interrupting the microbial metabolism of dietary choline and carnitine may be an important adjunctive approach to cardiovascular risk reduction. The study opens the door to combined strategies that pair dietary modification with microbial enzyme inhibition.

Human evidence distinguishes signal from noise.

By including a clinical trial, the study moved beyond the suggestive animal and in vitro data that had characterised much prior TMAO research. The demonstration of actual plaque regression, not merely biomarker reduction, in BBR-treated patients elevated the findings from biochemical observation to therapeutic evidence.

5. How This Research Can Help Humanity

A New Therapeutic Strategy for Cardiovascular Disease

The study validates the choline-TMA-TMAO pathway as a clinically actionable drug target. For the hundreds of millions of people worldwide with or at risk for atherosclerotic cardiovascular disease, berberine or dhBBR-derived compounds could represent a new class of therapy that complements existing treatments by attacking a distinct, microbiota-dependent disease mechanism .

Democratising Cardiovascular Prevention

Berberine is an inexpensive, widely available natural compound with a long history of safe human use. If the plaque-regression results are confirmed in larger trials, BBR could become an accessible cardiovascular preventive agent, particularly in regions where newer, expensive pharmaceuticals are unavailable or unaffordable.

A Template for Microbiome-Targeted Drug Discovery

The methodological framework established by this study, particularly the demonstration of the dhBBR redox cycling mechanism, provides a blueprint for discovering and characterising other natural products that act through gut microbial enzyme inhibition. The "vitamin-like" concept may be applicable to compounds beyond berberine.

Integrating Nutrition, Microbiome, and Pharmacology

The study elegantly connects diet (dietary choline and carnitine), the gut microbiome (TMA-producing bacteria and their enzymes), and pharmacology (BBR/dhBBR inhibition of CutC and FMO) into a unified therapeutic model. This integration points toward a future in which cardiovascular care is personalised based on an individual's gut microbial composition, TMAO production capacity, and dietary patterns.

Reducing the Global Burden of Atherosclerosis

Atherosclerosis underlies heart attacks, strokes, and peripheral artery disease, which collectively cause the largest proportion of global mortality. A safe, affordable, oral agent that reduces plaque progression through a mechanism distinct from existing therapies could meaningfully contribute to reducing this burden, especially when added to existing treatment regimens .

6. Final Summary

Most Important Takeaways

1. A nearly unabsorbed drug produces systemic cardiovascular benefit by acting on gut bacteria.

Berberine, with less than one percent oral bioavailability, reduces atherosclerotic plaque not by entering the bloodstream but by inhibiting the bacterial enzymes CutC and FMO within the gut lumen. This resolves a decades-long mechanistic puzzle and re-frames poor absorption as a therapeutic asset when the drug target resides in the microbiota .

2. The vitamin-like dhBBR/BBR redox cycle sustains inhibition.

Gut bacterial nitroreductase converts BBR to dhBBR, the active enzyme inhibitor. After dhBBR inhibits CutC and FMO, it is oxidised back to BBR, which can be re-reduced, creating a self-sustaining catalytic cycle analogous to vitamin C cycling. This mechanism allows low, intermittent dosing to maintain ongoing TMAO suppression .

3. Dual enzymatic inhibition blocks the entire TMAO pathway in the gut.

DhBBR inhibits both CutC/CutD (choline to TMA) and FMO (TMA to TMAO) within gut bacteria, attacking the atherogenic metabolite cascade at two sequential points. This dual targeting may contribute to the potency of TMAO reduction .

4. Clinical plaque regression was demonstrated, not just biomarker reduction.

In a small but significant clinical trial, four months of oral BBR reduced atherosclerotic plaque scores by 3.2 percent while standard therapy patients' plaque scores increased by 1.9 percent. Plasma TMAO dropped by 35 percent, linking the gut microbial mechanism to clinical disease modification .

5. The gut microbiome TMAO pathway is a validated therapeutic target.

The study provides the first complete translational evidence, from enzyme target to human plaque regression, that pharmacologically inhibiting microbial TMA/TMAO production treats atherosclerosis. This opens a new avenue for cardiovascular drug development .

Action Points

For Researchers and Drug Developers:

· Investigate the vitamin-like mechanism for other natural products: Screen poorly bioavailable natural compounds for similar redox-cycling interactions with gut microbial enzymes. The dhBBR/BBR paradigm may explain the efficacy of other traditional medicines.

· Develop direct CutC/FMO inhibitors: Use dhBBR as a lead compound for structure-based drug design targeting the choline-TMA lyase enzyme complex. More potent or selective inhibitors may produce even greater TMAO suppression.

· Conduct larger clinical trials: The 21-patient BBR trial requires replication in larger, multi-centre, randomised, placebo-controlled studies with longer follow-up to confirm plaque regression and assess cardiovascular event reduction.

· Personalise therapy by gut microbiome profiling: Investigate whether baseline TMAO production capacity, CutC gene abundance, or specific TMA-producing bacterial strains predict individual response to BBR or similar interventions.

For Clinicians:

· Recognise TMAO as an independent risk factor: The evidence that TMAO promotes atherosclerosis is robust, and its reduction may represent an additional therapeutic goal beyond LDL cholesterol and blood pressure control.

· Consider BBR as an adjunctive option: While larger confirmatory trials are needed, BBR's long safety record and the mechanistic and clinical data presented in this study suggest it may be a reasonable consideration for motivated patients with residual risk despite standard therapy.

· Counsel on dietary sources of TMA precursors: Educate patients that red meat, eggs, and organ meats are the primary dietary sources of choline and carnitine that fuel microbial TMA/TMAO production, and that dietary modification and pharmacotherapy may synergise.

For Individuals Concerned About Cardiovascular Health:

· Understand the diet-gut-heart connection: The foods you eat feed not only your body but your gut bacteria, some of which produce metabolites that directly affect your blood vessels. This research adds scientific weight to the long-standing advice to moderate red meat and animal product consumption.

· Exercise caution with self-supplementation: While BBR is available over the counter in some regions, clinical guidance is essential. Dosing, purity, drug interactions, and individual health status all require professional assessment.

· Support gut microbial health broadly: Diets rich in fibre and plant diversity may favour a gut microbial community less dominated by TMA-producing bacterial strains, providing a dietary foundation that complements any future pharmacological interventions.

For Public Health and Regulatory Bodies:

· Fund TMAO-targeted cardiovascular research: The pathway represents a novel public health target distinct from traditional risk factors. Investment in this area could yield complementary population-level prevention strategies.

· Evaluate BBR for essential medicine status: If larger trials confirm efficacy, BBR's low cost and safety profile may make it a candidate for inclusion in essential medicines lists for cardiovascular prevention in low-resource settings.

· Integrate microbiome science into dietary guidelines: As mechanistic understanding of diet-microbiota-host interactions grows, national dietary guidelines should begin incorporating recommendations grounded in gut microbial metabolic pathways.

-x-x-

Recommended Follow-Up Study

The dhBBR Cardiovascular Outcomes Trial

A large, multi-centre, randomised, double-blind, placebo-controlled trial of dhBBR (or a standardised BBR preparation) in patients with established atherosclerosis and elevated baseline TMAO levels is the critical next step. This trial would enrol several thousand participants across diverse populations and assign them to dhBBR or placebo on a background of standard cardiovascular care including statins. The primary outcome would be a composite of major adverse cardiovascular events: myocardial infarction, stroke, cardiovascular death, and hospitalisation for unstable angina. Secondary outcomes would include change in atherosclerotic plaque volume measured by CT angiography or intravascular ultrasound, changes in plasma TMAO, and changes in gut microbial CutC gene abundance. Such a trial would definitively establish whether TMAO-lowering therapy reduces clinical events and would provide the evidence needed for guideline inclusion and regulatory approval.

List of Other Related / Connected Studies and Research

The Hazen Laboratory TMAO Foundational Studies (Wang et al., 2011; Koeth et al., 2013; Tang et al., 2013)

Stanley Hazen's group at the Cleveland Clinic published a series of landmark papers that established the TMAO-atherosclerosis connection. They first identified TMAO as a novel independent risk factor for cardiovascular disease, demonstrated that dietary choline and carnitine drive TMAO production through gut microbial metabolism, and showed that TMAO directly promotes atherosclerosis and thrombosis in animal models. These studies provided the foundational rationale for targeting the TMAO pathway therapeutically .

DMB as a CutC Inhibitor (Wang et al., 2015)

The Hazen laboratory identified 3,3-dimethyl-1-butanol (DMB) as a non-lethal competitive inhibitor of CutC that suppresses TMAO production and attenuates atherosclerosis in mice. DMB served as the positive control comparator in the berberine study and established the precedent that CutC inhibition is a viable anti-atherosclerosis strategy. The berberine research extended this concept by identifying dhBBR as a significantly more potent natural CutC inhibitor .

The Li et al. Berberine-TMAO Study (2021)

A complementary study led by Li and colleagues, published in npj Biofilms and Microbiomes in 2021, independently demonstrated that BBR attenuates TMA/TMAO production and atherosclerosis in choline-fed ApoE knockout mice through gut microbiome remodelling. This study provided convergent evidence from a separate research group, strengthening confidence in the berberine-TMAO-atherosclerosis connection .

The Xie et al. Berberine-Thrombosis Study (2021)

Published in the European Journal of Pharmacology, this study demonstrated that BBR reduces TMAO-induced platelet hyperreactivity and arterial thrombosis risk through gut microbiota remodelling and CutC reduction. It extends the cardiovascular protective effects of BBR from atherosclerosis to thrombosis, another critical component of cardiovascular events .

The DIABIMMUNE and Planetary Health Karelia Studies

Earlier monographs in this series explored how the gut microbiome and environmental microbial exposures shape immune development and chronic disease risk. The berberine-TMAO study provides a direct mechanistic illustration of a principle established in those earlier works: that the gut microbiota serves as a critical interface between environmental inputs, including diet, and systemic host physiology. Where DIABIMMUNE showed that Bacteroides LPS can silently undermine immune education, the berberine study shows that specific gut bacterial enzymes can actively produce an atherogenic metabolite, and that both scenarios are amenable to intervention .

The MATADOR Study and Metabolic Regulation

The earlier monograph on the MATADOR study demonstrated that strategic interruption of continuous energy restriction could outmanoeuvre the body's metabolic defences against weight loss. The berberine study presents a conceptually parallel case in pharmacology: rather than overpowering a system with high drug concentrations, the vitamin-like redox cycling mechanism achieves sustained pathway inhibition through a subtle, regenerative interaction with the existing microbial metabolic machinery. Both studies illustrate the therapeutic value of working with, rather than against, evolved biological systems.

Protein Intake and TMAO Production

The Nunes et al. protein meta-analysis, the subject of the previous monograph, examined protein intake's effects on muscle mass. Interestingly, high-protein diets, particularly those rich in animal sources, may incidentally increase TMAO production through their choline and carnitine content. The berberine study suggests that the cardiovascular risk potentially associated with high animal protein intake could be pharmacologically or nutritionally mitigated by TMAO-pathway inhibition, connecting these previously separate areas of nutritional science.